Chen Bai-Song, Xie Hua, Zhang Sheng-Li, Geng Hong-Quan, Zhou Jun-Mei, Pan Jun, Chen Fang
Department of Urology, Children's Hospital of Shanghai, Children's Hospital affiliated to Shanghai Jiao Tong University, Shanghai - PR China.
Int J Artif Organs. 2011 Dec;34(12):1137-46. doi: 10.5301/ijao.5000069.
This study assessed the use of vascular endothelial growth factor (VEGF) gene-modified endothelial progenitor cells (EPCs) seeded onto bladder acellular matrix grafts (BAMGs), to enhance the blood supply in tissue-engineered bladders in a porcine model.
Autologous porcine peripheral EPCs were isolated, cultured, expanded, characterized, and modified with the VEGF gene using an adenovirus vector. The expression of VEGF was examined using reverse transcriptase polymerase chain reaction (RT-PCR) and an enzyme-linked immunosorbent assay (ELISA). VEGF gene modified EPCs were seeded onto BAMG and cultured for 3 days before implantation into pigs for bladder tissue engineering. A partial bladder cystectomy was performed in 12 pigs. The experimental group (6 pigs) received VEGF gene-modified EPC-seeded BAMG. The control group (6 pigs) received BAMG without seeded EPCs. The resulting tissue-engineered bladders were subject to a general and histological analysis. Microvessel density (MVD) was assessed using immunohistochemistry.
The ex vivo transfection efficiency of EPCs was greater than 60%-70% when concentrated adenovirus was used. The genetically modified cells expressed both VEGF and green fluorescent protein (GFP). Scanning electron microscopy (SEM) and Masson's trichrome staining of cross sections of the cultured cells seeded to BAMG showed cell attachment and proliferation on the surface of the BAMG. Histological examination revealed bladder regeneration in a time-dependent fashion. Significant increases in MVD were observed in the experimental group, in comparison with the control group.
VEGF-modified EPCs significantly enhanced neovascularization, compared with BAMG alone. These results indicate that EPCs, combined with VEGF gene therapy, may be a suitable approach for increasing blood supply in the tissue engineering of bladders. Thus, a useful strategy to achieve a tissue-engineered bladder is indicated.
本研究评估了接种于膀胱脱细胞基质移植物(BAMG)上的血管内皮生长因子(VEGF)基因修饰的内皮祖细胞(EPC)在猪模型中增强组织工程膀胱血液供应的作用。
分离、培养、扩增猪自体外周血EPC,进行鉴定,并使用腺病毒载体用VEGF基因对其进行修饰。采用逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附测定(ELISA)检测VEGF的表达。将VEGF基因修饰的EPC接种到BAMG上,培养3天后植入猪体内用于膀胱组织工程。对12头猪进行部分膀胱切除术。实验组(6头猪)接受接种VEGF基因修饰EPC的BAMG。对照组(6头猪)接受未接种EPC的BAMG。对所得的组织工程膀胱进行大体和组织学分析。采用免疫组织化学评估微血管密度(MVD)。
使用浓缩腺病毒时,EPC的体外转染效率大于60%-70%。基因修饰的细胞同时表达VEGF和绿色荧光蛋白(GFP)。扫描电子显微镜(SEM)和接种到BAMG上的培养细胞横截面的Masson三色染色显示细胞附着并在BAMG表面增殖。组织学检查显示膀胱以时间依赖性方式再生。与对照组相比,实验组的MVD显著增加。
与单独的BAMG相比,VEGF修饰的EPC显著增强了新生血管形成。这些结果表明,EPC与VEGF基因治疗相结合可能是增加膀胱组织工程中血液供应的合适方法。因此,提示了一种实现组织工程膀胱的有用策略。